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Background: Cardiovascular diseases (CVD) are leading causes of mortality and morbidity among Indigenous
people in New Zealand, Australia and Canada and are a major driver of the inequities in life expectancy between
Indigenous and non-Indigenous people in these countries. Evidence-based pharmaceutical management of CVD
can significantly reduce mortality and morbidity for persons diagnosed with CVD or for those at intermediate or
high risk of CVD. Health literacy has been identified as a major barrier in the communication and implementation
of appropriate pharmaceutical management plans for CVD. Addressing health literacy is particularly relevant in
Indigenous populations where there are unique health and adult literacy challenges.
Methods/design: This study will examine the effect of a customized, structured CVD medication programme,
delivered by health professionals, on the health literacy of Indigenous people with, or at risk, of CVD. Primary
outcomes are patient’s knowledge about CVD medications; secondary outcomes examine changes in health literacy
skills and practices. The study will employ a multi-site pre-post design with multiple measurement points to assess
intervention efficacy. Participants will be recruited from four Indigenous primary care services in Australia, Canada
and New Zealand. Three educational sessions will be delivered over four weeks. A tablet application will support
the education sessions and produce a customized pill card for each participant. Participants will be provided with
written information about CVD medications. Medication knowledge scores, and specific health literacy skills and
practices will be assessed before and after the three sessions. Statistical analyses will identify significant changes in
outcomes over each session, and from the pre-session one to post-session three time points.
Discussion: This study will make an important contribution to understanding the effect of a structured primary
care-based intervention on CVD health literacy in Indigenous populations. The study also illustrates the
incorporation of Indigenous health research principles and processes in clinical trials and provides insights that
may be useful in other contexts.
Trial registration: Australian and New Zealand Clinical Trials Register (ACTRN12612001309875; date of
registration 18/12/2012).
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Cardiovascular diseases are major causes of mortality
and hospitalisation for adult Indigenous peoples. Signifi-
cant inequalities in CVD morbidity, mortality and the
prevalence of cardiovascular disease risk factors between
Indigenous and non-Indigenous populations have been
documented in Australia [1] Canada [2], and New Zealand
[3,4]. Explicit evidence-based guidelines for the manage-
ment of CV risk factors and CVD have been available
for many years. Healthy nutrition, exercise, smoking cessa-
tion, and medications are the key strategies of primary and
secondary prevention. Initiatives such as explicit evidence-
based CVD management guidelines [5], health provider
education [6] and computerised decision support tools
[7-11] have been implemented to assist health profes-
sionals and health services to provide high quality CVD
care. However, CVD are chronic diseases and as such,
the patient and their family are the primary ‘managers’ of
these diseases. Self-management is central to effective
CVD management [12]. A complex array of skills, know-
ledge and psycho-social factors influence a person’s ability
to be an effective self-manager of chronic conditions [13].
Knowledge about CVD risk factors and medications is
essential to self-management. Published literature on
patients’ knowledge focuses on CVD risk factors and un-
derstanding of CVD risk assessment rather than know-
ledge and understanding of medications and their use
[14-18]. Available evidence suggests that intermittent and
non-adherence with medications is common and is as-
sociated with worse outcomes, including poorer control
of risk factors, increased hospitalisations, morbidity and
mortality [19-22].
Health literacy, defined as “the ability to access, under-
stand and act on information for health” [23], is an im-
portant contributor to knowledge, self-management, and
health outcomes generally [24-30] and for CVD [31].
The Institute of Medicine has reported that differences
in health literacy alone account for 25–30 per cent of
ethnic differences in health outcomes [32]. International
surveys have found that the majority of the population
in Australia, Canada and New Zealand (NZ) have inad-
equate levels of health literacy to effectively engage in health
care. In NZ, Māori have higher health literacy needs than
non-Māori [33,34]. While rigorous population based
Indigenous data are lacking in Australia and Canada, the
situation for Indigenous peoples in both countries is likely
to be similar to New Zealand given the known inequities
in health and education [35].
The intervention used in this trial was designed during
a developmental phase. This included in-depth inter-
views with community members who were taking CVD
prevention medications to ascertain their knowledge
about their medications, what they would like to know
about these medications, and how they would like to beprovided with this information. There were significant
knowledge gaps at all four locations and, while there was
some locality variation, the knowledge gaps and expressed
information needs were remarkably similar across sites.
The data from these interviews were used to develop the
intervention. Interviews with health professionals were
also undertaken and explored their awareness and under-
standing of health literacy and how they addressed health
literacy in their practice. Environmental scans have
assessed the baseline health literacy demands the health
service environment places on its clients. Data from health
professional interviews and environmental scans will allow
assessment of whether changes in health professionals’
awareness, knowledge and practices and changes in the
health literacy environment may contribute to the results
of the intervention trial.
Study aims
The aim of this study is to test the effect of a customized,
structured CVD medication programme, delivered by health
professionals, on the related health literacy of Indigenous
people with, or at risk, of CVD. Primary outcomes are
patient’s knowledge about CVD medications. Secondary
outcomes examine changes in health literacy skills and prac-
tices. The programme will be implemented in Indigenous
primary health care services in Australia (one service),
Canada (one service with two sites), and NZ (two ser-
vices). The intervention will be delivered by nurses in NZ
and Canada, and a researcher/health educator in Australia.
Methods and design
The intervention trial utilizes a single arm pre-post de-
sign with multiple measurement points. Two factors re-
lated to the size of the local Indigenous communities
preclude the use of randomised, controlled trial design.
Firstly, there is a high likelihood of contamination be-
tween control and intervention groups in the Indigenous
communities where the trial will be located. Secondly,
the use of a control group is not feasible in these commu-
nities because the eligible population is relatively small
and, in order to have sufficient participants receiving the
intervention, all eligible people will have to receive it. The
uniqueness of local Indigenous communities and their
health services precluded the use of quasi-experimental
design with matched primary care service controls located
elsewhere.
Indigenous community engagement in the research
process
In keeping with ethical requirements and evidence based
best practices for Indigenous research [36-39], as well as
some site’s own research policies [40,41], the participat-
ing Indigenous communities have been involved in the
development of the project from its inception.
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Indigenous peoples and all the Indigenous researchers
have pre-existing relationships with the participating In-
digenous health services where the research will be
based. These services were involved in all aspects of pro-
ject development including decisions to submit a grant
application, development of the application, study design,
and the implementation of phase one of the project.
Key staff from the health services are project co-
investigators, and the intervention will be delivered by
Indigenous staff employed by the health services. In all
three countries specific policies and processes regarding
project governance and implementation; health service
provider/community expectations; benefits of the re-
search; ownership, control, and access to research infor-
mation, and dissemination of project results, including
academic publications, have been agreed.
Ethics
The study design and implementation processes were
reviewed and approved by each of the four participating
Indigenous health services. The study was approved by
the Health and Disabilities Ethics Committees in NZ
(MEC/10/061/EXP), the Human Research Ethics Com-
mittee (HREC) at the University of Melbourne, Australia
and the Saint Michael’s Hospital Research Ethics Board,
Toronto, Canada. The study was registered with the
Australian and New Zealand Clinical Trials Register on
18th December 2012 (ACTRN12612001309875).
Study locations
The study will be implemented in four Indigenous health
services (five sites) across the three countries. In NZ,
one service (Te Hononga o Tamaki me Hoturoa) is lo-
cated in a large metropolitan city that provides nurse-led
services but does not provide primary medical care ser-
vices. Participants from this service will be drawn from
nurse-led programmes for people with long-term condi-
tions and for people recently discharged from hospital
with a diagnosis of a CVD event. The second NZ site is
located in a remote rural area whose health services are
provided by Ngati Porou Hauora, an Indigenous health
provider that delivers a range of primary care services
including medical services.
The Australian partner is the Victorian Aboriginal Health
Service (VAHS). VAHS is an urban community controlled
Aboriginal health service that was established in 1973
to address the specific medical needs of local Victorian
Aboriginal communities. VAHS now provides a compre-
hensive range of medical, dental and social services and
supports the well-being of the community through contri-
butions to community events and activities.
The Canadian study partner is the Dedwadadehsnye > s
Aboriginal Health Access Centre (DAHAC), a provinciallyfunded urban Indigenous health service which provides
primary health care, traditional healing and health promo-
tion programs to Indigenous people living in the cities of
Hamilton and Brantford, Ontario. Recruitment and inter-
vention will occur at both DAHAC sites, which are 40 km
apart and have similarly structured primary health care
services.
Recruitment
Medical records at the sites will be systematically searched
to identify potentially eligible patients. These patients will
be contacted by a health service staff member who is not
directly involved in the project and asked if they would
like to know more about the trial. Patients who accept this
invitation will then be contacted by the nurse/health edu-
cator who will provide information about the study and
undertake formal consent procedures with patients that
agree to participate. Participants will be able to invite fam-
ily members to sit in on the sessions; however, data will
not be collected from family members.
Eligibility
Patient participants are eligible for the trial if they are
Indigenous adults ≥ 20 years of age and are enrolled with
the participating health services. In addition they need
to have been diagnosed with angina pectoris, myocardial
infarction, transient ischaemic attacks or stroke OR (for
Canada and Australia only) were known to be at risk of
a CVD event and receiving medication to manage this
risk. In Australia these participants were eligible if they
were at high risk (≥15 % risk of a CVD event in the next
five years) [36]. In Canada participants were eligible if
they were assessed as having at least internediate risk
(≥15 % risk of an event in the next 10 years) [42,43].
Finally, all participants need to be taking at least two of
the following types of medicines: a statin, aspirin, a beta
blocker, or an ACE inhibitor. Eligible participants will be
excluded from the trial if they have a condition which
means they are unable to provide informed consent or
they have a cognitive deficit that interferes with their
ability to participate in the intervention.
Power analysis
A power analysis that allows for the conduct of country
specific analyses was undertaken. Hill-Briggs [44] found
that a literacy adapted diabetes and CVD education inter-
vention among an urban African American population re-
sulted in a change in mean knowledge score from 2.7 ±
1.7 to 4.7 ± 2.0 (maximum score possible = 9) among
people with low health literacy. Assuming the proposed
intervention will result in small to medium improvements
in medication knowledge and health literacy practices, the
minimum sample size required at each of the five sites to
detect an effect size of 0.4 respectively for mean pre-post
Table 1 Summary of trial contacts and data collection
Time point Measurement
Enrolment visit. T0 Consent and enrolment in study. In Canada
baseline demographic and clinical information
was also collected at this visit
Session one. T1 Baseline demographic and clinical information
(NZ, Australia)
Pre-session one medication knowledge and
health literacy practices
T2 Post session one medication knowledge and
health literacy practices




Health literacy practices between sessions one and two
T4 Post session two medication knowledge and
health literacy practices




Health literacy practices between sessions two
and three
T6 Post session three medication knowledge and
health literacy practices
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52. For an effect size of 0.3, 90 patients would be needed.
Our recruitment targets are, therefore, 100 participants at
each of the two NZ sites, 100 participants in Australia,
and 120 at each Canadian site.
Intervention
The intervention consists of an educational session deliv-
ered by health professionals who will have received train-
ing in health literacy, and strategies to support knowledge
acquisition and the development of health literacy skills
using adult education principles. A booklet, designed by
the medical and health literacy research team members,
will be provided to participants. It includes information
about CVD, and medication use in general (including pre-
scription labels, side effects, keeping medicines safely, tak-
ing medicines safely, and interactions). The booklet also
contains specific information about the four CVD medica-
tion classes (statins, aspirin, beta blockers, and ACE inhib-
itors) including the scientific and brand names of the
medications, what the medication does, how to take it, in-
teractions, side effects, contraindications to taking the
medicine, what to do if experiencing a serious side effect,
how to know if the treatment is working, and lipid and
blood pressure treatment targets.
An interactive tablet application has been developed for
use during each session. This tablet ensures that the nurse/
educator covers the CVD medication information in a
structured way and provides interactive opportunities for
the participant. The application also prints out a participant
specific pill card with images of their medications. A list of
three participant identified questions for use next time they
see their health professional is also printed. In the context
of the trial the application will also ensure that information
is provided in a standardised manner across all sites.
The written resource and tablet information were stan-
dardized across all three countries, however images and
background graphic design features varied with local Indi-
genous culture and language being used in each country.
Participants will only cover information about the
medication classes they are currently taking. That is, if
they are currently taking a statin and an ACE inhibitor
they will cover these two medication types but will not
receive information about aspirin and beta blockers.
The education session will be delivered on three occa-
sions at intervals determined using adult education prin-
ciples to optimise learning opportunities. The second
session is scheduled to occur seven days after the first
but can be completed up to two weeks after the sched-
uled date. The third session is scheduled to occur 28 days
after the first session but can be completed up to four
weeks after the scheduled date.
The time required to complete each session will vary
depending on the number of medications the participantis taking. We anticipate that each session will be no less
than 30 minutes and no more than 75 minutes.
Training for research staff will be provided in New
Zealand (NZ and Australian research staff ) and in Canada.
Training sessions with research staff from all three coun-
tries will also be undertaken using teleconferences and
Skype. Training will be provided in health literacy, princi-
ples of adult learning, the delivery of the intervention, and
all trial protocols and processes including data collection
and quality assurance processes. A detailed training man-
ual will be provided. Training in use of the medication
knowledge outcome measures will include the use of stan-
dardized scenarios that will be pre-scored by two investiga-
tors (SC, SR). Each nurse/educator will score the scenario
using the relevant medication knowledge outcomes mea-
sures. This process will continue with supplementary train-
ing where needed until accuracy and cross-site concordance
in scoring is reached. To evaluate scoring practices during
the trial this process will be repeated at regular intervals
using standardized video scenarios.
Main study outcomes
The primary study outcome measures will assess changes
from baseline to data collection time points for: (1) patient
knowledge about the CVD medication classes they are
taking; (2) patient knowledge of their treatment targets for
lipids and blood pressure; and (3) the use of participant-
specified questions with their usual healthcare provider.
Secondary outcomes measures will examine changes in
patient health literacy skills and practices. Table 1 de-
scribes the data collected at the measurement points.
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Baseline demographic, medical history, medication infor-
mation, blood pressure and lipid recordings will be col-
lected at the enrolment session or at the start of the first
session (T0 or T1 in Table 1). Outcome assessment tools
that assess patient knowledge of the scientific and brand
name of their medications, class of drug, function of
drug, important side effects, special instructions for tak-
ing the medicine, and (where relevant) knowledge of
lipid and BP treatment targets have been developed for
statin, aspirin, beta blockers and ACE inhibitors and will
be completed immediately before and after each educa-
tion session (T1-T6).
Participants’ health literacy skills and practices during
each outcome assessment will be assessed (T1-T6). Par-
ticipants will be asked about their health literacy prac-
tices prior to the first session and between each session
(T0/T1, T3 and T5). Participants will be asked about
their use of their questions for health professionals at
the beginning of the second and third sessions (T3 and
T5).
Statistical analyses
Descriptive statistics will describe the baseline character-
istics of study participants (age, sex, CVD diagnosis, co-
morbidities, medications), baseline blood pressure and
lipid measures, and the characteristics of the sessions with
respect to location (home/office) and whether or not fam-
ily members were present. Finally we will describe the
baseline health literacy skills and practices of participants
including how and from where/whom they acquire infor-
mation CVD medications.
To assess the effect of the intervention on patient
knowledge about their medication we will examine the
mean knowledge scores for each of the four CVD medi-
cation groups over time. We will test changes in mean
scores from pre session one (T1) to post session three
(T6). Baseline characteristics of participants who en-
rolled but did not complete the study will be compared
to participants who finished the intervention to examine
whether drop out was determined by specific character-
istics or not.
Discussion
In all three countries data obtained in the developmental
phase showed significant gaps in patients’ cardiovascular
medication knowledge that are likely to interfere with safe
and effective medication use. Improving health literacy
about CVD medications is one of a range of strategies ne-
cessary to reduce the inequitable burden of cardiovascular
disease experienced by Indigenous populations. This study
will determine if health professional delivered, health lit-
eracy oriented educational sessions delivered in the
primary care setting enhances medication knowledgeand health literacy practices within Indigenous commu-
nities in Australia, Canada and New Zealand. If successful
the intervention may also be useful for a wider range of
medications associated with other long-term conditions
and in non-Indigenous contexts.
The study is one of the first international clinical trials
conducted solely among Indigenous populations. Building
on previously published work about Indigenous involve-
ment in clinical trials [45] the protocol illustrates the ap-
plication of Indigenous health research principles and
protocols [46], such as Indigenous involvement across all
roles and throughout the entire project, to clinical trials.
Implementation of these principles and processes requires
appropriate relationships and communication with the
health services, their staff and the study participants. The
use of outcomes measures that assess the development of
knowledge, skills and practices is informed by Indigenous
preferences for strength-based rather than deficit focused
research. This strength-based approach is also consistent
with Nutbeam’s [30] approach to health literacy.
The study design also illustrates one approach to imple-
menting clinical trials in distinctive local contexts. In
Canada, networks of friends and family have been iden-
tified by members of our research team as the most
important source of health information in diverse local
Indigenous communities [47]. Furthermore, the relatively
small population sizes of these communities means that,
in order to have a sufficient sample to assess the effect of
the intervention, it will have to be delivered to all eligible
people in the health services. The study design needs to
accommodate both these challenges, making a single arm,
pre-post design with case studies of the surrounding envi-
ronments for factors that may influence the effect of the
trial, the most suitable design. Similar challenges may be
encountered in other studies that are located in relatively
small, local populations.
A key audience for our study results will be the Indigenous
health service providers who are responsible for providing
care to the patients in the study. We will work with these
health service provider partners to interpret the study
findings and identify recommendations for their practice.
We will also share our study findings more broadly with
Indigenous and non-Indigenous health policy makers,
practitioners, and researchers.
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